Loading...

DMRA DAMORA THERAPEUTICS INC Management Changes 8-K Filing

DMR

DMR

DAMORA THERAPEUTICS INC

(DMRA)

2026 8-K

Management Changes

Accounting Firm Change

Management Changes

Name Change Announcement

Stock Offering Announcement

Management Change

Investor Conference Update

Management Changes

Correction Filing

Merger Completion

Board Appointment

Asset Acquisition

Nasdaq Compliance

Annual Meeting Results

Deficiency Letter from Nasdaq

Positive trial results for ...

Clinical Trial Update

Restructuring Plan and Stra...

Phase 2b GALACTIC-1 Trial R...

Annual Meeting Results

FDIC Takeover of Silicon Va...

Financial Update

External Links:

On February 6, 2026, Galecto, Inc. announced that Hans T. Schambye will step down as CEO effective February 10, 2026, with Sherwin Sattarzadeh appointed as interim CEO. Additionally, the company increased its authorized shares from 300 million to 500 million after stockholder approval on February 9, 2026.

AI Assistant

DAMORA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.